Recent News

• 03.10.2025 - Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
• 03.10.2025 - Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy
• 03.06.2025 - Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases
• 03.06.2025 - Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases
• 03.03.2025 - TD Cowen 45th Annual Health Care Conference
• 03.03.2025 - TD Cowen 45th Annual Health Care Conference
• 02.28.2025 - Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)
• 02.28.2025 - Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)
• 02.25.2025 - Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
• 02.25.2025 - Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

Recent Filings

• 03.07.2025 - 424B7 Prospectus [Rule 424(b)(7)]
• 03.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 144 Report of proposed sale of securities
• 03.03.2025 - 144 Report of proposed sale of securities
• 02.14.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors